Highest-materiality recent filing
Filing contains no material event; XBRL annual report data only
Filing under Items 8.01 and 9.01 provides Inline XBRL for FY 2025 annual report.
Stryker CAO Berry to retire Sept 1, 2026; Baculik named successor as VP, CAO
William Berry retires as VP, CAO effective Sept 1, 2026; will serve as Advisor to CFO until Aug 15, 2027.
Stryker shareholders elect directors, ratify auditor, approve exec compensation
All ten director nominees elected; Emmanuel P. Maceda had highest dissent with 52.4M against (out of ~290M votes cast).
Stryker Q1 net sales $6.0B up 2.6%; adjusted EPS down 8.5% to $2.60; maintains FY guidance
Net sales $6.0B (+2.6% reported, +2.4% organic); MedSurg/Neuro +5.0%, Orthopaedics +0.1%.
Incident identified March 11, 2026; caused business disruptions.
Stryker updates cyber incident: contained, no customer data accessed per Unit 42
Threat actor used malicious file to hide activity; file not capable of spreading internally or externally.
Stryker updates on cyber incident: operations disrupted, patient services unaffected
Cybersecurity incident affecting Microsoft environment disclosed March 11; CISO provided update March 12.
Stryker reports global cybersecurity incident affecting Microsoft systems; investigation ongoing
Incident detected March 11, 2026; global disruption to Microsoft environment; no ransomware or malware; contained.
Stryker reports Q4 2025 sales $7.2B, +11% organic; 2026 outlook 8-9.5% organic growth
Q4 reported EPS $2.20 (+56% YoY); adjusted EPS $4.47 (+11.5%).
Spencer Stiles appointed President & COO effective Jan 1, 2026; will lead global businesses, strategy, and M&A.
Stryker Q3 net sales +10.3% to $6.1B; raises FY 2025 guidance
Reported EPS $2.22 (+2.8%); adjusted EPS $3.19 (+11.1%).
Stryker Q2 2025: net sales $6.0B +11.1%, adj EPS $3.13 +11.4%, raises FY guidance
Net sales $6.0B +11.1% reported (+10.2% organic); MedSurg/Neuro +17.3%, Orthopaedics +2.0% (ex-spinal +10.7%).
Stryker shareholders approve equity plan amendments, increase share reserves at 2025 annual meeting
Shareholders approved 2011 Long-Term Incentive Plan amendment, increasing shares available and extending duration, effective May 8, 2025.
Reported net sales $5.9B (+11.9% YoY); organic net sales +10.1%.
Stryker enters $3.0B revolving credit facility maturing 2030, replacing prior deal
$3.0B aggregate commitments with maturity February 25, 2030.
Stryker completes $4.94B cash acquisition of Inari Medical
Closed acquisition of Inari Medical for ~$4.94 billion in cash on Feb 19, 2025.
Stryker issues $3B in notes; $1.8B earmarked for Inari Medical acquisition
Issued $500M 4.550% notes due 2027, $700M 4.700% notes due 2028, $800M 4.850% notes due 2030, $1B 5.200% notes due 2035.
Stryker board member Allan Golston to retire at May 8, 2025 annual meeting
Allan Golston informed Stryker of his retirement from the Board effective as of the May 8, 2025 Annual Meeting.
Stryker Q4 adjusted EPS up 15.9% to $4.01, organic sales +10.2%; guides 2025 8-9% growth
Reported EPS fell 52.7% to $1.41 due to $818M goodwill/impairment charges on Spine; adjusted EPS rose 15.9% to $4.01.
Stryker CFO Glenn Boehnlein to retire April 1, 2025; Preston Wells promoted as successor
CFO Glenn Boehnlein retires after 22 years; will advise CEO through March 2026 at $800k salary plus $215k bonus.
Stryker to acquire Inari Medical for $80/share cash, ~$4.9B equity value
Stryker will pay $80 per share in cash for all outstanding Inari shares; total fully diluted equity value ~$4.9B.
Stryker Q3 beats: adj EPS $2.87 (+16.7%), sales $5.5B (+11.5% organic), raises FY guidance
Reported net sales $5.5B, +11.9% reported, +11.5% organic; adjusted EPS $2.87, +16.7%.
Stryker completes €1.4B and $1.5B dual-tranche note offerings; proceeds to repay near-term debt
Issued €800M 3.375% notes due 2032, €600M 3.625% notes due 2036, $750M 4.250% notes due 2029, and $750M 4.625% notes due 2034.
Stryker Q2 2024: organic sales +9.0%, adj. EPS $2.81, raises FY guidance
Net sales $5.4B (+8.5% reported, +9.0% organic); MedSurg Neuro +9.7% organic, Ortho Spine +8.0% organic.
All ten director nominees elected with votes ranging from 291.9M to 304.9M in favor.
Reported EPS $2.05 (+33.1%); adjusted EPS $2.50 (+16.8%).
Stryker Q4 organic sales up 11.4%; FY23 revenue $20.5B; guides FY24 adj EPS $11.70-$12.00
Q4 organic net sales growth 11.4% to $5.8B; full year organic growth 11.5% to $20.5B.
Stryker completes €600M offering of 3.375% Notes due 2028
Issued €600M aggregate principal of 3.375% Notes due December 11, 2028.
Stryker issues $600M 4.850% Notes due Dec 2028; net proceeds ~$594M for general purposes
$600M aggregate principal of 4.850% Notes maturing Dec 8, 2028; interest payable semiannually June 8 and Dec 8 starting June 8, 2024.
Stryker Q3 net sales $4.9B (+9.6%), adjusted EPS $2.46 (+16.0%), raises FY guidance
Reported net sales $4.9B, +9.6% YoY; organic net sales +9.2%.
Net sales $5.0B, +11.2% reported, +11.9% organic; adj. EPS $2.54 (+12.9%).
Stryker amends credit agreement to transition from LIBOR to SOFR benchmarks
Amendment No. 1 to Oct 2021 Credit Agreement replaces LIBOR with SOFR-based rates and adds conforming changes.
Stryker shareholders elect all directors, approve say-on-pay, reject political disclosure
All ten directors elected with majority support; Rajeev Suri received highest votes (312.1M), Kevin Lobo lowest (302.4M).
Stryker Q1 organic sales +13.6%; raises FY growth guidance to 8-9%
Reported net sales $4.8B, +11.8% reported, +13.6% organic; MedSurg/Neuro +12.4%, Ortho+Spine +15.2%.
Stryker Q4 organic sales +13.2%, adj. EPS $3.00; FY23 adj. EPS guide $9.85-10.15
Q4 reported sales $5.2B (+10.7% YoY); organic sales +13.2% driven by MedSurg and Neurotechnology (+16.9% organic).
Stryker amends bylaws to adopt universal proxy card rules
Board adopted amended bylaws effective November 1, 2022.
Stryker Q3 organic sales +9.9% to $4.5B; adj EPS $2.12 -3.6%; guides FY adj EPS $9.15-$9.25
Net sales $4.5B (+7.7% reported, +9.9% organic); MedSurg & Neuro +10.8% organic, Ortho & Spine +8.7%.
Stryker Q2 organic sales +6.1% to $4.5B; lowers FY adjusted EPS guidance to $9.30-$9.50
Reported net sales of $4.5B (+4.6% YoY); organic net sales +6.1%.
Stryker shareholders elect all 10 director nominees, ratify Ernst & Young
All 10 director nominees elected with > 94% of votes cast for each; Kevin Lobo received lowest support at 95.5%.
Stryker appoints Sherilyn S. McCoy as Lead Independent Director, effective May 4, 2022
Allan C. Golston steps down as Lead Independent Director after six years; Sherilyn S. McCoy succeeds.
Stryker Q1 sales up 9.2% organic to $4.3B; lowers adjusted EPS guidance to lower end of $9.60-$10.00
Reported net sales $4.3B (+8.1%), organic +9.2%; MedSurg +10.8%, Orthopaedics and Spine +7.2%.
Stryker enters $1.5B term loan agreement maturing 2025
Borrowed full $1.5B on Feb 22, 2022; maturity Feb 22, 2025.
Stryker completes acquisition of Vocera Communications for ~$3.1B
Completed acquisition of Vocera Communications on Feb 23, 2022 for total consideration of ~$3.1B including repayment of convertible notes.
Stryker Q4 sales $4.7B (+10.3%), FY21 adj. EPS $9.09 (+22.3%); forecasts FY22 adj. EPS $9.60-10.00
Q4 net sales $4.7B, +10.3% YoY; organic +9.0% vs 2020, +6.2% vs 2019.
Stryker realigns into MedSurg/Neurotechnology and Orthopaedics/Spine segments effective Dec 31, 2021
Segments reflect new internal structure after COO transition; Pierce leads MedSurg/Neuro, Stiles leads Ortho/Spine.
Stryker agrees to acquire Vocera Communications for $79.25 per share in cash
Stryker to acquire Vocera Communications for $79.25 per share in cash via tender offer and merger.
$1.85 per share Dutch dividend withholding tax was withheld from Wright shareholders exchanging shares for cash in the merger.
Stryker Q3: adj EPS $2.20 (+2.8%); organic sales +4.5%; China impairment $105M; guidance revised
Net sales $4.2B, +11.3% vs 2020; organic net sales +4.5% vs 2020 and +8.4% vs 2019.
Stryker announces retirement of President and COO Timothy Scannell, leadership changes
President and COO Timothy J. Scannell to retire on March 31, 2023; will serve as Advisor to CEO from Oct 1, 2021.
Stryker Q2 net sales $4.3B (+55% YoY), raises FY2021 guidance
Reported net sales $4.3B, +55.4% from 2020 and +17.6% from 2019; organic net sales +42.9% from 2020.
Emily Baculik, who currently serves as Vice President, Corporate Controller, will also serve as chief accounting officer of the Company effective September 1, 2026
William E. Berry, Jr. has decided to retire from his role as Vice President, Chief Accounting Officer of the Company effective September 1, 2026
On February 4, 2025, Allan Golston, a member of the Board of Directors (the “Board”) of Stryker Corporation (the “Company”), informed the Company that he will retire from the Board effective as of the Company’s annual meeting of shareholders expected to be held on May 8, 2025
Glenn S. Boehnlein has decided to retire from his role as Vice President, Chief Financial Officer of the Company effective April 1, 2025
Preston W. Wells, who currently serves as Vice President, Group Chief Financial Officer for Orthopaedics, has been promoted to Vice President, Chief Financial Officer of the Company effective April 1, 2025
On December 4, 2023, Dr. Srikant Datar, a member of the Board of Directors (the “Board”) of the Company, informed the Company that he will retire from the Board effective as of the Company’s annual meeting of shareholders expected to be held on May 9, 2024 (the “Annual Meeting”).
Timothy J. Scannell, President and Chief Operating Officer of the Company, has notified the Company of his intent to retire on March 31, 2023.
Effective October 1, 2021, Kevin A. Lobo, the Chair and Chief Executive Officer of the Company, will also become President of the Company.
Effective October 1, 2021, Mr. Scannell will transition from his current role of President and Chief Operating Officer to the position of Advisor to the Chief Executive Officer of the Company.
Max materiality 0.85 · Median 0.72 · Most common event earnings